1) Couzin-Frankel J. (2013) Breakthrough of the year 2013. Cancer immunotherapy. Science, 342, 1432–1433.
2) Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, et al. (1996) Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes. Int. Immunol., 8, 765–772.
3) Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, et al. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J. Exp. Med., 192, 1027–1034.
4) Nishimura H, Honjo T. (2001) PD-1: an inhibitory immunoreceptor involved in peripheral tolerance. Trends Immunol., 22, 265–268.
5) Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, et al. (2001) PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat. Immunol., 2, 261–268.
6) Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, et al. (2016) Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet, 387, 1837–1846.
7) 吉田隆雄, 幸田健一, 中尾進太郎, 大山行也. (2015) 新規免疫チェックポイント阻害薬ヒト型抗ヒトPD-1抗体ニボルマブ（オプジーボ®点滴静注20 mg，100 mg）の薬理学的特性および臨床効果. 日薬理誌, 146, 106–114.
8) Okazaki T, Chikuma S, Iwai Y, Fagarasan S, Honjo T. (2013) A rheostat for immune responses: The unique properties of PD-1 and their advantages for clinical application. Nat. Immunol., 14, 1212–1218.
9) Hino R, Kabashima K, Kato Y, Yagi H, Nakamura M, et al. (2010) Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer, 116, 1757–1766.
10) Iwai Y, Ishida M, Tanaka Y, Okazaki T, Honjo T, et al. (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A., 99, 12293–12297.
11) Iwai Y, Terawaki S, Honjo T. (2005) PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol., 17, 133–144.
12) Shitara K, Özgüroğlu M, Bang YJ, Di Bartolomeo M, Mandalà M, et al. (2018) Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro- oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet, 392, 123–133.
13) Ribas A, Wolchok JD. (2018) Cancer immunotherapy using checkpoint blockade. Science, 359, 1350–1355.
14) Robert C, Long G V, Brady B, Dutriaux C, Maio M, et al. (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med., 372, 320– 330.
15) Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, et al. (2015) Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N. Engl. J. Med., 373, 123–135.
16) Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, et al. (2015) Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N. Engl. J. Med., 373, 1627–1639.
17) Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, et al. (2015) Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N. Engl. J. Med., 373, 1803–1813.
18) Tang J, Yu JX, Hubbard-Lucey VM, Neftelinov ST, Hodge JP, et al. (2018) Trial watch: The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors. Nat. Rev. Drug. Discov., 17, 854–855.
19) Chen DS, Mellman I. (2013) Oncology meets immunology: The cancer-immunity cycle. Immunity, 39, 1–10.
20) Ribas A, Wolchok JD. (2018) Cancer immunotherapy using checkpoint blockade. Science, 359, 1350–1355.
21) Topalian SL, Taube JM, Anders RA, Pardoll DM. (2016) Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer., 16, 275–287.
22) Scharping NE, Menk A V, Whetstone RD, Zeng X, Delgoffe GM. (2017) Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia. Cancer Immunol. Res., 5, 9–16.
23) Chowdhury PS, Chamoto K, Kumar A, Honjo T. (2018) PPAR-Induced Fatty Acid Oxidation in T Cells Increases the Number of Tumor-Reactive CD8. Cancer Immunol. Res., 6, 1375–1387.
24) Tu MM, Lee FYF, Jones RT, Kimball AK, Saravia E, et al. (2019) Targeting DDR2 enhances tumor response to anti-PD-1 immunotherapy. Sci. Adv., 5, eaav2437.
25) Manguso RT, Pope HW, Zimmer MD, Brown FD, Yates KB, et al. (2017) In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature, 547, 413–418.
26) Wang C, Thudium KB, Han M, Wang XT, Huang H, et al. (2014) In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol. Res., 2, 846–856.
27) Li Y, Carpenito C, Wang G, Surguladze D, Forest A, et al. (2018) Discovery and preclinical characterization of the antagonist anti-PD-L1 monoclonal antibody LY3300054. J. Immunother. Cancer., 6, 31.
28) Stecher C, Battin C, Leitner J, Zettl M, Grabmeier-Pfistershammer K, et al. (2017) PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells. Front. Immunol., 8, 572.
29) Selby MJ, Engelhardt JJ, Johnston RJ, Lu LS, Han M, et al. (2016) Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS One, 11, e0161779.
30) Woo SR, Turnis ME, Goldberg M V, Bankoti J, Selby M, et al. (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res., 72, 917–927.
31) Qin S, Xu L, Yi M, Yu S, Wu K, et al. (2019) Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4. Mol. Cancer, 18, 155.
32) Bell J. Amlexanox for the treatment of recurrent aphthous ulcers. (2005) Clin. Drug Investig., 25, 555–566.
33) Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, et al. (2002) Expression of programmed death 1 ligands by murine T cells and APC. J. Immunol., 169, 5538– 5545.
34) Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW, et al. (2003) Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J. Pharmacol. Exp. Ther., 305, 1222– 1232.
35) Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, et al. (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat. Biotechnol., 26, 317–325.
36) Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, et al. (2017) IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J. Clin. Invest., 127, 2930– 2940.
37) Davis AA, Patel VG. (2019) The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J. Immunother. Cancer, 7, 278.
38) Jiang P, Gu S, Pan D, Fu J, Sahu A, et al. (2018) Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat. Med., 24, 1550–1558.
39) Terness P, Chuang JJ, Opelz G. (2006) The immunoregulatory role of IDO-producing human dendritic cells revisited. Trends Immunol., 27, 68–73.
40) Tokunaga R, Zhang W, Naseem M, Puccini A, Berger MD, et al. (2017) CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. Cancer Treat. Rev., 63, 40–47.
41) Shi H, Han X, Sun Y, Shang C, Wei M, et al. (2018) Chemokine (C-X-C motif) ligand 1 and CXCL2 produced by tumor promote the generation of monocytic myeloid- derived suppressor cells. Cancer Sci., 109, 3826–3839.
42) Bronte V, Brandau S, Chen SH, Colombo MP, Frey AB, et al. (2016) Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat. Commun., 7, 12150.
43) Sangaletti S, Tripodo C, Sandri S, Torselli I, Vitali C, et al. (2014) Osteopontin shapes immunosuppression in the metastatic niche. Cancer Res., 74, 4706–4719.
44) Reilly SM, Chiang SH, Decker SJ, Chang L, Uhm M, et al. (2013) An inhibitor of the protein kinases TBK1 and IKK-ɛ improves obesity-related metabolic dysfunctions in mice. Nat. Med., 19, 313–321.
45) Jenkins RW, Aref AR, Lizotte PH, Ivanova E, Stinson S, et al. (2017) Profiling of PD- 1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov., 8, 196–215.
46) Xiao Y, Zou Q, Xie X, Liu T, Li HS, et al. (2017) The kinase TBK1 functions in dendritic cells to regulate T cell homeostasis, autoimmunity, and antitumor immunity. J. Exp. Med., 214, 1493–1507.
47) Terawaki S, Chikuma S, Shibayama S, Hayashi T, Yoshida T, et al. (2011) IFN-α directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J. Immunol., 186, 2772–2779.
48) Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, et al. (2016) Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade. Cell, 167, 1540-1554.
論文の公開元へ
